SBI Securities’s Eterna Therapeutics ERNA Stock Holding History

SBI Securities’s Portfolio ERNA Stock Details ERNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7	Buy	+1	New	+$7	﹤0.01%	3945
2026 Q1	–	Hold	0	–	–	–	3979
2025 Q2	–	Hold	0	–	-$2	–	4167
2025 Q1	–	Hold	0	–	–	–	4089
2024 Q4	–	Hold	0	–	–	–	4035

Other funds holding ERNA

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

DIG

Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

Tradewinds Capital Management Bellingham, Washington $563M AUM 41.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

SBI Securities's ERNA Position: Q2 2026 in Review

SBI Securities opened a new position in Eterna Therapeutics (ERNA) in Q2 2026: 1 share worth $7. The stake represents ﹤0.01% of the portfolio and ranks #3945 among its holdings.

9 funds tracked by Wall St. Rank hold ERNA as of Q2 2026.

SBI Securities held 1 share of Eterna Therapeutics worth $7 as of Q2 2026.
Eterna Therapeutics was a new SBI Securities position in Q2 2026.
Eterna Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3945 holding.
9 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.